| Purpose | Sentis Lung Cancer Panel (Tissue, 20 Genes) Test that enables highly accurate mutation detection across most clinically relevant genes associated with lung cancer. The panel allows highly sensitive detection of actionable mutations in 20 genes from tissues, providing a comprehensive molecular profiling of lung cancer for clinicians.Genes: BRCA1, BRCA2, CHEK2, HOXB13, MSH2, MSH6, PMS2, MLH1, ATM, BRIP1, PALB2, MRE11A, NBN, RAD51C, RAD51D, ATR, FAM175A, GEN1, MUTYH, TP53, EPCAM, FANCA, CDK12. |
| Test Code | DX0664 |
| Turnaround Time (TAT) | 20 Days |
| Sample Tested | Sentis Lung Cancer Panel (Tissue, 20 Genes) - >60 mg Tissue OR FFPE (10mm x 10mm) (5-10uM) Sections OR 2-3 Samplings of biopsy OR >500ng good quality Tumor DNA
|
| Methodology | - DNA Extraction and QC.
- Targeted Capture of 20 genes associated with Lung Cancer.
- Highly sensitive detection of actionable mutations from tissues in 20 genes associated with lung cancer.
- Reports having information for targeted drugs (Precision Medicine).
- Genetic Counselling.
|
| Advantages | - All exons plus flanking intronic regions covered for all genes tested (20 genes associated with lung cancer); one single assay that detects point mutations, deletions, insertions, duplications, rearrangements.
- A streamlined sample-to-results workflow with MGI’s platform and automated on-premises NGS bioinformatics system, enabling effortless obtainment of insightful reports from samples.
- Providing molecular evidence for the consideration of more than 42 targeted therapies (Precision Medicine).
- Pathology check conducted on each FFPE sample to ensure good representation of tumor cell being Tested Sequencing Depth >500X coverage (Tissue).
|
